Accutar Biotech stands out as a trailblazer, reshaping the way we approach drug discovery in the biotechnology sector. With a deep-rooted commitment to innovation, Accutar combines advanced artificial intelligence (AI) with traditional laboratory techniques to drive the next generation of healthcare solutions. By harnessing AI's power to analyze and decode complex biological systems, Accutar Biotech is making strides toward faster, more efficient drug development—one that could revolutionize the pharmaceutical industry.

A Vision Rooted in Data and Efficiency

Accutar Biotech's philosophy is built on a simple yet profound principle: to leverage data-driven insights to accelerate drug discovery. This vision is the driving force behind the company’s cutting-edge research and technology. By using a hybrid approach that combines computational drug design with wet lab validation, Accutar aims to significantly reduce the time and costs typically associated with traditional drug development methods. This seamless integration of digital tools and hands-on experimentation allows the company to streamline processes, bringing life-saving drugs to market faster and more affordably.

The company's commitment to data-driven solutions is exemplified through its state-of-the-art systems and revolutionary technologies. Accutar's groundbreaking work in AI applications has placed it at the forefront of biotech innovation, positioning the company to make a lasting impact on the industry for years to come.

ChemiRise: Revolutionizing Organic Compound Synthesis

One of Accutar Biotech's most significant innovations is ChemiRise, an end-to-end retrosynthesis system designed to propose complete retrosynthesis routes for organic compounds swiftly and reliably. Retrosynthesis, the process of deconstructing a compound into simpler components, plays a crucial role in drug discovery, as it helps scientists understand the most efficient way to synthesize a target molecule.

ChemiRise stands out by using a machine learning model trained on a database of over 3 million organic reactions. This extensive dataset, which includes patented reactions and experimental data, enables ChemiRise to suggest precise and optimized synthesis routes. By using a graph convolutional neural network-based algorithm, ChemiRise efficiently determines the best reaction pathways, accelerating the process of drug development and production.

Notably, the system’s atom-mapping algorithm and one-step reaction proposer have demonstrated superior performance when benchmarked against previous methods. In practical applications, ChemiRise has proven capable of producing reliable retrosynthesis routes that are validated by human experts. This not only boosts the productivity of drug discovery teams but also promises to transform the way organic synthesis is approached in biotech labs worldwide.

Orbital: Redefining Molecular Docking with Deep Neural Networks

Another breakthrough technology from Accutar Biotech is Orbital, a deep neural network-based docking platform that revolutionizes the process of drug docking. Traditional molecular docking, which is used to predict the binding affinity of a drug to its target protein, can be a time-consuming and computationally intensive task. However, Orbital simplifies this process to an extraordinary level, allowing researchers to perform docking with just a single click.

Unlike traditional docking methods that rely on complex energy equations and multiple manual steps, Orbital utilizes a dynamic deep neural network framework. This approach eliminates the need for tedious preparations, such as ligand preparation, target grid definition, and hydration. The platform’s ability to conduct docking with such precision and speed has made it a game-changer in the industry.

With Orbital, users only need to provide the ligand in simplified molecular-input line-entry system (SMILES) format and the target protein, and the platform handles the rest. What’s more impressive is the speed at which Orbital operates—the average running time for a drug docking case is under one minute on a standard laptop. This makes it an incredibly efficient tool for accelerating drug discovery and identifying potential therapeutic candidates more quickly than ever before.

The Future of Drug Discovery

Accutar Biotech is not just pushing the boundaries of what’s possible in biotechnology; it’s redefining the very way drugs are developed and brought to market. With a focus on combining the power of AI with traditional experimental techniques, the company is leading the charge toward a more efficient, faster, and cost-effective future in drug discovery.

The development of ChemiRise and Orbital highlights Accutar's unique ability to merge the digital and physical worlds of science, using AI to solve complex biological puzzles and create novel solutions. By reducing the time and cost associated with drug discovery, Accutar is not only advancing the biotech field but also opening new possibilities for treatments that could change the lives of millions around the world.

As the biotech industry continues to evolve, Accutar Biotech’s innovations are paving the way for a future where new drugs can be discovered and developed in a fraction of the time it traditionally takes. The company’s unwavering commitment to excellence and groundbreaking technology positions it as one of the top biotech companies to watch in 2025 and beyond.

Dr. Jie Fan, PhD | Founder and Chief Executive Officer

Dr. Jie Fan was trained at the University of California, Berkeley in biostatistics and obtained his Doctorate degree from the Weill Cornell Graduate School of Medical Sciences and the Memorial Sloan Kettering Cancer Center in structural biology and immunology. He received further training with the Nobel Prize-winning biologist, Dr. Günter Blobel, at the Rockefeller University in New York. With the dream of using a hybrid approach, combining computation design and experimental validation, to accelerate drug discovery and aiming to reform the current “hit-to-lead” drug discovery process, Jie founded Accutar Biotech with the support of Dr. Günter Blobel.

"We combine artificial intelligence with traditional drug discovery methods to accelerate the development of life-saving drugs. Our goal is to reduce the time and cost of drug development, making it easier and faster to bring new treatments to patients around the world."